Cargando…
Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer
Background: Metastatic CRC (mCRC) is a molecular heterogeneous disease. The aim of this review is to give an overview of molecular-driven treatment of mCRC patients. Methods: A review of clinical trials, retrospective studies and case reports was performed regarding molecular biomarkers with therape...
Autores principales: | Lai, Eleonora, Liscia, Nicole, Donisi, Clelia, Mariani, Stefano, Tolu, Simona, Pretta, Andrea, Persano, Mara, Pinna, Giovanna, Balconi, Francesca, Pireddu, Annagrazia, Impera, Valentino, Dubois, Marco, Migliari, Marco, Spanu, Dario, Saba, Giorgio, Camera, Silvia, Musio, Francesca, Ziranu, Pina, Puzzoni, Marco, Demurtas, Laura, Pusceddu, Valeria, Dettori, Manuela, Massa, Elena, Atzori, Francesco, Dessì, Mariele, Astara, Giorgio, Madeddu, Clelia, Scartozzi, Mario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281737/ https://www.ncbi.nlm.nih.gov/pubmed/32413973 http://dx.doi.org/10.3390/cancers12051214 |
Ejemplares similares
-
Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021) -
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment
por: Spanu, Dario, et al.
Publicado: (2022) -
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not?
por: Pretta, Andrea, et al.
Publicado: (2022) -
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors
por: Ziranu, Pina, et al.
Publicado: (2023) -
How to improve metastatic pancreatic ductal adenocarcinoma patients’ selection: Between clinical trials and the real-world
por: Pretta, Andrea, et al.
Publicado: (2022)